TRUE Private Wealth Advisors Has $726,000 Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

TRUE Private Wealth Advisors raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.8% in the 4th quarter, Holdings Channel reports. The firm owned 1,368 shares of the medical research company’s stock after purchasing an additional 166 shares during the quarter. TRUE Private Wealth Advisors’ holdings in Thermo Fisher Scientific were worth $726,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of TMO. Moneta Group Investment Advisors LLC raised its position in shares of Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after acquiring an additional 8,347,260 shares in the last quarter. Providence Capital Advisors LLC raised its position in shares of Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock worth $10,136,000 after acquiring an additional 5,832,730 shares in the last quarter. Norges Bank bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $3,105,677,000. Morgan Stanley grew its stake in shares of Thermo Fisher Scientific by 17.7% in the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after buying an additional 1,764,312 shares during the period. Finally, International Assets Investment Management LLC grew its stake in shares of Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock valued at $535,923,000 after buying an additional 1,008,045 shares during the period. 89.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. HSBC lifted their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. The Goldman Sachs Group lifted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Raymond James lifted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Stock Down 1.3 %

NYSE TMO opened at $547.25 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The stock has a market capitalization of $208.89 billion, a PE ratio of 35.42, a PEG ratio of 2.33 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The business’s 50-day moving average is $571.57 and its 200 day moving average is $527.01.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same period last year, the business posted $5.40 earnings per share. Thermo Fisher Scientific’s quarterly revenue was down 4.9% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Insiders Place Their Bets

In other news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the sale, the chief executive officer now owns 43,608 shares of the company’s stock, valued at $24,011,436.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last three months. Company insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.